Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator

A physiologically based pharmacokinetic (PBPK) model was developed to evaluate and predict (1) the effect of concomitant cytochrome P450 3A (CYP3A) inhibitors or inducers on the exposures of zanubrutinib, (2) the effect of zanubrutinib on the exposures of CYP3A4, CYP2C8, and CYP2B6 substrates, and (...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kun, Yao, Xueting, Zhang, Miao, Liu, Dongyang, Gao, Yuying, Sahasranaman, Srikumar, Ou, Ying C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129716/
https://www.ncbi.nlm.nih.gov/pubmed/33687157
http://dx.doi.org/10.1002/psp4.12605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129716/
https://www.ncbi.nlm.nih.gov/pubmed/33687157
http://dx.doi.org/10.1002/psp4.12605

Ejemplares similares